You are here

BLUEWILLOW BIOLOGICS INC

Company Information
Address
2311 GREEN RD STE A
ANN ARBOR, MI 48105-2965
United States


http://www.bluewillow.com/

Information

UEI: RL3UZ5ZDKFT8

# of Employees: 13


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No




Success Stories

  1. SBIR-STTR-Success: Vaccine Company Develops Nasal Antiseptic That Kills Coronavirus in Lab Studies

    NIH-funded company BlueWillow Biologics is working to develop vaccines that have traditionally been difficult to make, including a vaccine for anthrax and one for Respiratory Syncytial Virus (RSV), a virus that mostly infects children and the elderly. But years of vaccine research have also led to...

Award Charts




Award Listing

  1. Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein

    Amount: $1,726,088.00

    ABSTRACTRespiratory syncytial virus (RSV) is extremely ubiquitous, with almost all humans acquiring the infection by the age of two.It is manifested by several secondary acute respiratory illnesses in ...

    SBIRPhase II2022Department of Health and Human Services National Institutes of Health
  2. Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein

    Amount: $299,650.00

    ABSTRACTRespiratory syncytial virus (RSV) is extremely ubiquitous, with almost all humans acquiring the infection by the age of two.It is manifested by several secondary acute respiratory illnesses in ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  3. Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine

    Amount: $2,980,942.00

    ABSTRACT Genital herpes simplex virus-2 (HSV-2) infections are a major public health problem affecting rt40 million people in the United States and rt500 million globally. HSV-2 infection is character ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  4. DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY. PHASE

    Amount: $2,995,800.00

    Food allergy is an emerging health problem with increasing incidence and severity, particularly in children, and continuing throughout adulthood. Since 1990, the incidence of self-reported peanut alle ...

    SBIRPhase II2020Department of Health and Human Services National Institutes of Health
  5. Development of Nanvas TM (Oil in Water Nanoemulsion Adjuvant) Formulated Allergens as Intranasal Immunotherapeutic Vaccines for Peanut Allergy

    Amount: $299,888.00

    Food allergy is an emerging health problem with increasing incidence and severityparticularly in childrenand continuing throughout adulthoodSincethe incidence of self reported peanut allergy has risen ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  6. Development of a nanoemulsion-based vaccine for chlamydia infection

    Amount: $215,532.00

    AbstractChlamydia trachomatis is the most commonly reported bacterial infection in the United States and in many other parts of the worldBecause untreated infection in women causes long term problems ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  7. Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine

    Amount: $1,492,764.00

    ABSTRACT Genital herpes simplex virusHSVinfections are a major public health problem affecting rtmillion people in the United States and rtmillion globallyHSVinfection causes recurringgenital sores th ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Nanoemulsion-based vaccine for chronic hepatitis B virus

    Amount: $297,250.00

    DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is the most common cause of chronic viral liver disease worldwide. More than 370 million people are chronically infected with HBV leading t ...

    STTRPhase I2010Department of Health and Human Services National Institutes of Health
  9. Determine and Confirm the Field Use Protocol for NANOProtect ¿Non-Toxic Decontaminate for Facilities and Equipment Following Bio Attack

    Amount: $225,000.00

    NanoBio Corporation¿s antimicrobial nanoemulsion technology was developed by Dr. James R. Baker at the University of Michigan Medical School over a period of seven years. Reschard was funded by gran ...

    SBIRPhase II2005Environmental Protection Agency
  10. Determine and Confirm the Field Use Protocol for NanoProject Non-Toxic Decontaminate for Facilities and Equipment Following a Bio-Incident

    Amount: $224,665.60

    NanoBio Corporation’s antimicrobial nanoemulsion technology was developed by Dr. James R. Baker at the University of Michigan Medical School over a period of 7 years. Research was funded throu ...

    SBIRPhase II2005Environmental Protection Agency
US Flag An Official Website of the United States Government